EMA signs off on 3 drugs recently rejected by FDA, including BioMarin’s new hemophilia gene therapy

The EMA’s human medicines committee on Friday recommended three new drugs for approval or conditional approval, even as their US counterparts have rejected these three for various reasons.

In a major move, CHMP offered a thumbs up to a conditional marketing authorization for the first gene therapy to treat severe...

Click to view original post